<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26309127</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.</ArticleTitle><Pagination><StartPage>e0136328</StartPage><MedlinePgn>e0136328</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0136328</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0136328</ELocationID><Abstract><AbstractText>The four serotypes of dengue virus (DENV1-4) pose a serious threat to global health. Cross-reactive and non-neutralizing antibodies enhance viral infection, thereby exacerbating the disease via antibody-dependent enhancement (ADE). Studying the epitopes targeted by these enhancing antibodies would improve the immune responses against DENV infection. In order to investigate the roles of antibodies in the pathogenesis of dengue, we generated a panel of 16 new monoclonal antibodies (mAbs) against DENV4. Using plaque reduction neutralization test (PRNT), we examined the neutralizing activity of these mAbs. Furthermore, we used the in vitro and in vivo ADE assay to evaluate the enhancement of DENV infection by mAbs. The results indicate that the cross-reactive and poorly neutralizing mAbs, DD11-4 and DD18-5, strongly enhance DENV1-4 infection of K562 cells and increase mortality in AG129 mice. The epitope residues of these enhancing mAbs were identified using virus-like particle (VLP) mutants. W212 and E26 are the epitope residues of DD11-4 and DD18-5, respectively. In conclusion, we generated and characterized 16 new mAbs against DENV4. DD11-4 and D18-5 possessed non-neutralizing activities and enhanced viral infection. Moreover, we identified the epitope residues of enhancing mAbs on envelope protein. These results may provide useful information for development of safe dengue vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Chung-Tao</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Mei-Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chien-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Wen-Fan</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chiung-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ping-Chang</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, United States Department of Health and Human Services, Fort Collins, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chung</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019067" MajorTopicYN="N">Antibody-Dependent Enhancement</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26309127</ArticleId><ArticleId IdType="pmc">PMC4550467</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0136328</ArticleId><ArticleId IdType="pii">PONE-D-15-10679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013; 496(7446):504&#x2013;7. 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009; 9(11):678&#x2013;87. 10.1016/S1473-3099(09)70254-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(09)70254-3</ArticleId><ArticleId IdType="pubmed">19850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988; 239(4839):476&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11(3):480&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007; 104(22):9422&#x2013;7. 10.1073/pnas.0703498104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0703498104</ArticleId><ArticleId IdType="pmc">PMC1868655</ArticleId><ArticleId IdType="pubmed">17517625</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol. 2011; 23(3):391&#x2013;8. 10.1016/j.coi.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.03.005</ArticleId><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990; 44:649&#x2013;88. 10.1146/annurev.mi.44.100190.003245</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez DE, De Lella Ezcurra AL, Fucito S, Gamarnik AV. Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology. 2005; 339(2):200&#x2013;12. 10.1016/j.virol.2005.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.06.009</ArticleId><ArticleId IdType="pubmed">16002117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu WW, Kinney RM, Dreher TW. Control of translation by the 5'- and 3'-terminal regions of the dengue virus genome. J Virol. 2005; 79(13):8303&#x2013;15. 10.1128/JVI.79.13.8303-8315.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.13.8303-8315.2005</ArticleId><ArticleId IdType="pmc">PMC1143759</ArticleId><ArticleId IdType="pubmed">15956576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008; 319(5871):1834&#x2013;7. 10.1126/science.1153264</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153264</ArticleId><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Chang GJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004; 78(24):13975&#x2013;86. 10.1128/JVI.78.24.13975-13986.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13975-13986.2004</ArticleId><ArticleId IdType="pmc">PMC533943</ArticleId><ArticleId IdType="pubmed">15564505</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009; 4(4):e4991 10.1371/journal.pone.0004991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol. 2002; 169(2):657&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12097367</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu IJ, Chiu CY, Chen YC, Wu HC. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem. 2011; 286(11):9726&#x2013;36. 10.1074/jbc.M110.170993</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.170993</ArticleId><ArticleId IdType="pmc">PMC3058979</ArticleId><ArticleId IdType="pubmed">21233208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010; 84(18):9227&#x2013;39. 10.1128/JVI.01087-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01087-10</ArticleId><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010; 84(20):10630&#x2013;43. 10.1128/JVI.01190-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01190-10</ArticleId><ArticleId IdType="pmc">PMC2950583</ArticleId><ArticleId IdType="pubmed">20702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010; 6(4):e1000823 10.1371/journal.ppat.1000823</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, Chiu CY, et al. Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2. PLoS Negl Trop Dis. 2012; 6(5):e1636 10.1371/journal.pntd.0001636</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001636</ArticleId><ArticleId IdType="pmc">PMC3341331</ArticleId><ArticleId IdType="pubmed">22563515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5):717&#x2013;25. S0092867402006608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003; 100(12):6986&#x2013;91. 10.1073/pnas.0832193100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol. 2001; 75(9):4268&#x2013;75. 10.1128/JVI.75.9.4268-4275.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.9.4268-4275.2001</ArticleId><ArticleId IdType="pmc">PMC114172</ArticleId><ArticleId IdType="pubmed">11287576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol. 2005; 3(1):13&#x2013;22. 10.1038/nrmicro1067</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1067</ArticleId><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007; 81(23):12816&#x2013;26. 10.1128/JVI.00432-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00432-07</ArticleId><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007; 366(2):349&#x2013;60. 10.1016/j.virol.2007.05.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.05.042</ArticleId><ArticleId IdType="pubmed">17719070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745&#x2013;8. 10.1126/science.1185181</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol. 2006; 176(5):2825&#x2013;32. 176/5/2825</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, Jan JT, et al. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol. 2003; 84:2771&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">13679612</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Huang HN, Lin CT, Chen YF, King CC, Wu HC. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007; 14(4):404&#x2013;11. 10.1128/CVI.00249-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00249-06</ArticleId><ArticleId IdType="pmc">PMC1865613</ArticleId><ArticleId IdType="pubmed">17287314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010; 7(2):128&#x2013;39. 10.1016/j.chom.2010.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.01.004</ArticleId><ArticleId IdType="pmc">PMC2824513</ArticleId><ArticleId IdType="pubmed">20153282</ArticleId></ArticleIdList></Reference><Reference><Citation>Purdy DE, Chang GJ. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology. 2005; 333(2):239&#x2013;50. 10.1016/j.virol.2004.12.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.12.036</ArticleId><ArticleId IdType="pubmed">15721358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008; 82(13):6631&#x2013;43. 10.1128/JVI.00316-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla T, Chan KR, Zhang SL, Tan HC, Lim AP, Hanson BJ, et al. Dengue virus neutralization in cells expressing fc gamma receptors. PLoS One. 2013; 8(5):e65231 10.1371/journal.pone.0065231</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065231</ArticleId><ArticleId IdType="pmc">PMC3661447</ArticleId><ArticleId IdType="pubmed">23717696</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012; 429: 12&#x2013;20. 10.1016/j.virol.2012.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3683589</ArticleId><ArticleId IdType="pubmed">22537810</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012; 109(19):7439&#x2013;44. 10.1073/pnas.1200566109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010; 8(3):271&#x2013;83. 10.1016/j.chom.2010.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003; 60:421&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010; 6(2):e1000790 10.1371/journal.ppat.1000790</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000790</ArticleId><ArticleId IdType="pmc">PMC2820409</ArticleId><ArticleId IdType="pubmed">20168989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, Freund NT, et al. Pepitope: epitope mapping from affinity-selected peptides. Bioinformatics. 2007; 23(23):3244&#x2013;6. 10.1093/bioinformatics/btm493</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm493</ArticleId><ArticleId IdType="pmc">PMC7110138</ArticleId><ArticleId IdType="pubmed">17977889</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013; 12(8):933&#x2013;53. 10.1586/14760584.2013.815412</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2013.815412</ArticleId><ArticleId IdType="pmc">PMC3773977</ArticleId><ArticleId IdType="pubmed">23984962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes HR, Crill WD, Chang GJ. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J. 2012; 9(1):115 10.1186/1743-422X-9-115</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-115</ArticleId><ArticleId IdType="pmc">PMC3424142</ArticleId><ArticleId IdType="pubmed">22709350</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol. 2012; 3:334 10.3389/fimmu.2012.00334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00334</ArticleId><ArticleId IdType="pmc">PMC3492872</ArticleId><ArticleId IdType="pubmed">23162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang CT, Li PC, Liu IJ, Liao MY, Chiu CY, Chao DY, et al. An epitope-substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2. PLoS Negl Trop Dis. 2015; 9(7): e0003903 10.1371/journal.pntd.0003903</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003903</ArticleId><ArticleId IdType="pmc">PMC4489899</ArticleId><ArticleId IdType="pubmed">26135599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>